Prevalence and Predictors of Kidney Disease, and Long-Term Renal Outcome in Pulmonary Hypertension
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pulmonary Hypertension
- Sponsor
- University of Giessen
- Enrollment
- 824
- Locations
- 1
- Primary Endpoint
- Changes in estimated glomerular filtration rate (GFR) in each class of pulmonary hypertension during follow-up period
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Evaluation of the prevalence of kidney disease, hemodynamic predictors and long-term renal outcome in patients with invasively diagnosed pulmonary hypertension.
Detailed Description
This study aims to determine the prevalence of kidney disease, hemodynamic predictors and long-term renal outcome of in-hospital patients with invasively diagnosed pulmonary hypertension at the Department of Pulmonology, University Hospital Giessen and Marburg, Giessen, Germany between 1999 and 2016.
Investigators
Faeq Husain
Senior Physician Nephrology
University of Giessen
Eligibility Criteria
Inclusion Criteria
- •older than 18 years
- •subjects with invasively diagnosed pulmonary hypertension at rest and available renal function and spot urine data at day of right heart catheterization between March 1999 and December 2016 at the Department of Pulmonology, University Hospital Giessen and Marburg, Giessen, Germany
Exclusion Criteria
- •subjects with estimated GFR \<15ml/min/1.73m2 or prior dialysis
- •pre-existing acute kidney injury
- •non-end stage renal disease with extracorporeal or peritoneal ultrafiltration due to diuretic-resistant fluid overload
- •primary kidney disease requiring active immunosuppression
- •autosomal dominant polycystic kidney disease
- •if subjects are pregnant
- •if subjects are recipients of solid-organ transplants
- •subjects with pulmonary hypertension with unclear/multifactorial mechanisms (WHO group 5 pulmonary hypertension)
Outcomes
Primary Outcomes
Changes in estimated glomerular filtration rate (GFR) in each class of pulmonary hypertension during follow-up period
Time Frame: 3 years follow-up
Estimated GFR (Chronic Kidney Disease Epidemiology Collaboration) will be used over follow-up period to determine changes in renal function
Impact of renal function on deterioration of pulmonary hypertension during follow-up period
Time Frame: 3 years follow-up
Changes in estimated GFR (Chronic Kidney Disease Epidemiology Collaboration) over follow-up period will be correlated with clinical worsening of pulmonary hypertension (as determined by echocardiography, 6-minute-walk, New York Heart Association classification, b-type natriuretic peptide)
Secondary Outcomes
- Impact of pulmonary hypertension-related morbidity on renal function decline(3 years follow-up)
- Impact of pulmonary hypertension-specific therapy on renal function decline(3 years follow-up)
- Prevalence of proteinuria in pulmonary hypertension(At baseline)